

Incident Cancer in Heart Failure Patients and the Need for Additional Investigations



Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

We read with interest the paper by Bertero et al,¹ which evaluated the risk of cancer in heart failure (HF) patients. This study examined 104,020 patients aged >50 years in Italy over a 16-year time frame. The results indicated an increased incidence rate of cancer in HF patients compared with control subjects (hazard ratio [HR]: 1.76, 95% CI: 1.71-1.81). However, an important variable not considered in this study was ethnicity because the population was limited to 1 area of Italy.¹

The conclusion of this study is corroborated by Roderburg et al,² in 2021, who found a similar association between HF and cancer (HR: 1.76 [95% CI: 1.71-1.81]; $P < 0.001$). However, the study by Roderburg et al evaluated additional cancer types and additional confounders, and found the strongest associations between HF and cancers of the pharynx, lip, and oral cavity (HR: 2.1 [95% CI: 1.66-2.17]; $P < 0.001$). HF was also associated with lung cancer and female gynecologic cancers (HR: 1.91 [95% CI: 1.74-2.10] and 1.86 [95% CI: 1.56-2.17], respectively; $P < 0.001$).² These cancer types warrant further investigation.

Leedy et al,³ in 2021, found a significant association between incident cancer in post-menopausal women aged 50 to 79 years with HF (HR: 1.28, 95% CI: 1.02-1.51) in lung, colorectal, and obesity-related cancers. Furthermore, there was an overall increased risk of incident cancer in patients with HF with preserved ejection fraction (HR: 1.34, 95% CI: 1.06-1.67).³ In future investigations, it will be important to incorporate various HF subtypes, and include men as well as younger patients.

*Sidharth Sunil Menon, MBBS, BSc
Mahmood Ahmad, MA

*University College London
1 Sunways
Mirfield WF14 9TN, United Kingdom
E-mail: sidharthsunilmenon@gmail.com
<https://doi.org/10.1016/j.jacc.2022.04.005>

Crown Copyright © 2022 Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug

REFERENCES

- Bertero E, Robusto F, Rulli E, et al. Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort. *J Am Coll Cardiol CardioOnc*. 2022;4(1):98-109.
- Roderburg C, Loosen SH, Jahn JK, et al. Heart failure is associated with an increased incidence of cancer diagnoses. *ESC Heart Fail*. 2021;8(5):3628-3633.
- Leedy DJ, Reding KW, Vasbinder AL, et al. The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative. *Eur J Heart Fail*. 2021;23(10):1712-1721.

REPLY: Perspectives and Limitations of the Studies of the Association Between Heart Failure and Cancer



We thank Drs Brahmabhatt and colleagues and Dr Menon and Mr Ahmad for their constructive comments on our paper.¹

We agree with Dr Brahmabhatt and colleagues that clonal hematopoiesis of indeterminate potential (CHIP) may be a possible mechanism linking cancer and cardiovascular disease. Indeed, CHIP-related variants both confer a proliferative advantage to hematopoietic progenitors and amplify the inflammatory response of the innate immune system. The proinflammatory phenotype of mature myeloid cells carrying CHIP-related variants might contribute to the enhanced atherosclerotic burden and increased risk for cardiovascular events observed in animal models and patients with CHIP.² Accordingly, one recent exploratory analysis suggested that in the CANTOS (Cardiovascular Risk Reduction Study [Reduction in Recurrent Major CV Disease Events]) trial, the effect of interleukin-1-beta inhibition with canakinumab on major adverse cardiovascular events was greater in patients with CHIP due to *TET2* variants.³ In addition, in rodent models of pressure overload-induced heart failure (HF), CHIP-related activation of the Nod-like receptor protein 3 inflammasome worsened maladaptive left ventricular remodeling, indicating that the inflammatory state associated with CHIP has detrimental effects on cardiac function even in the absence of atherosclerosis.⁴ Overall, experimental and clinical evidence implicates CHIP in the pathogenesis of both cardiovascular disease and hematologic malignancies.

As pointed out by Dr Menon and Mr Ahmad, one limitation of our analysis is that our study population is rather homogeneous with respect to ethnicity and

geography. Nonetheless, our results are corroborated by similar analyses performed in diverse regions, including the United States, Denmark, and Japan.^{5,6} Furthermore, we were unable to differentiate between HF with reduced and preserved ejection fraction, which is certainly relevant given the differences in etiology and pathophysiology of these 2 entities. However, we did include men and assessed whether sex influenced the excess risk for cancer in the HF population. In addition, and consistent with the study by Roderburg et al,⁷ we observed that patients with HF had a greater risk for incident head and neck cancers (HR: 1.35; 95% CI: 1.15-1.59) and increased mortality with cancers arising in the head and neck (HR: 1.92; 95% CI: 1.33-2.78) (reported in Supplemental Tables 7 and 8).

*Edoardo Bertero, MD, PhD

Pietro Ameri, MD, PhD

*IRCCS Ospedale Policlinico San Martino & Department of Internal Medicine
University of Genova

Viale Benedetto XV, 6

16132 Genova, Italy

E-mail: pietroameri@unige.it

<https://doi.org/10.1016/j.jacc.2022.05.004>

© 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the [Author Center](#).

REFERENCES

1. Bertero E, Robusto F, Rulli E, et al. Cancer incidence and mortality according to pre-existing heart failure in a community-based cohort. *J Am Coll Cardiol CardioOnc*. 2022;4:98-109.
2. Bertero E, Canepa M, Maack C, Ameri P. Linking heart failure to cancer: background evidence and research perspectives. *Circulation*. 2018;138:735-742.
3. Svensson EC, Madar A, Campbell CD, et al. *TET2*-driven clonal hematopoiesis and response to canakinumab: an exploratory analysis of the CANTOS randomized clinical trial. *JAMA Cardiol*. 2022;7(5):521-528.
4. Sano S, Oshima K, Wang Y, et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1beta/NLRP3 inflammasome. *J Am Coll Cardiol*. 2018;71:875-886.
5. Banke A, Schou M, Videbaek L, et al. Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. *Eur J Heart Fail*. 2016;18:260-266.
6. Sakamoto M, Hasegawa T, Asakura M, et al. Does the pathophysiology of heart failure prime the incidence of cancer? *Hypertens Res*. 2017;40:831-836.
7. Roderburg C, Loosen SH, Jahn JK, et al. Heart failure is associated with an increased incidence of cancer diagnoses. *ESC Heart Fail*. 2021;8:3628-3633.